Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HTR1A | P08908 | 7/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026463 | 0.88 | KMT2A (0.83) | KMT2AALDH1A1GFERMAPTHTR1A | |
| Hydrochloric Acid SCHEMBL7934846 | 0.87 | KMT2A (0.83) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL17549668 | 0.86 | KMT2A (0.84) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL3893679 | 0.85 | KMT2A (0.73) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL10432577 | 0.84 | ALDH1A1 (0.70) | KMT2AALDH1A1MAPTSLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7932173 | 0.84 | KMT2A (0.73) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL17549676 | 0.84 | KMT2A (0.71) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL17549664 | 0.84 | KMT2A (0.71) | KMT2AALDH1A1GFERMAPTHTR1A | |
| SCHEMBL12123912 | 0.83 | HTR1A (0.65) | KMT2AALDH1A1HTR1ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL8344861 | 0.83 | KMT2A (0.71) | KMT2AALDH1A1GFERMAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | KMT2A 903/4885ALDH1A1 3775/4885GFER 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.